Cephalosporins are bactericidal antibiotics and act by inhibiting cell wall synthesis. They inhibit a wide variety of gram-positive and gram-negative bacteria. They are considered broad-spectrum antibiotics with similar activities to those of ampicillin. They are sometimes grouped into generations by their antimicrobial properties. Cephalosporin drugs can be grouped into five classes or generations. The gram-negative antimicrobial property significantly increases with each newer generation of cephalosporin.
Technavio's analysts forecast the global cephalosporin drugs market to grow at a CAGR of 3.21% over the period 2014-2019.
Covered in this report
In this report, Technavio covers the present scenario and growth prospects of the global cephalosporin drugs market for 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various prescription drugs along with the generic drugs used for the treatment of various infectious diseases caused by the different strains of bacteria.
Technavio's report, Global Cephalosporin Drugs Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, APAC, and EMEA; it also covers the landscape of the global cephalosporin drugs market and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.
Technavio Announces the Publication of its Research Report – Global Cephalosporin Drugs Market 2015-2019
Technavio recognizes the following companies as the key players in the Global Cephalosporin Drugs Market: Allergan, Astellas, Bristol-Myers Squibb, GSK, Merck, Pfizer, Sandoz and Teva
Other Prominent Vendors in the market are: Abbott, Aspen Pharmacare, AstraZeneca, Aurobindo Pharma, Basilea Pharmaceuticals, Baxter, Biocon, Corden Pharma, Eli Lilly, F. Hoffmann-La Roche, Flynn Pharma, Hospira, Incepta Pharmaceuticals, Johnson & Johnson, Kyorin Pharmaceutical, Lupin Pharmaceuticals, Orchid Pharma, Par Pharmaceutical, Pernix Therapeutics, Sanofi, Shionogi, Sun Pharmaceutical, Takeda Pharma, Theravance Biopharma, and Wockhardt.
Commenting on the report, an analyst from Technavio’s team said: “The increased approvals and use of combination drugs is an emerging trend in the global cephalosporin drugs market. Combination therapies are found to show better efficacy than monotherapies. Also, the use of monotherapies leads to easy development of resistance. This can be avoided by the judicious use of combination drugs.”
According to the report, the increased awareness of diseases and their treatment options helps detect and treat infections during their early stages. The European Antibiotic Awareness Day is celebrated on November 18 every year to raise awareness about antibiotic resistance and promote the judicious use of antibiotics. Such programs about the disease and treatment options increase the treatment-seeking population, driving the growth of the market.
Further, the report states that most drugs in the cephalosporin market are generics, resulting in decreased revenue for the products. Some drugs that have expired and have a generic form as of today include cefuroxime axetil, ceftazidime, and cefprozil.
Allergan, Astellas, Bristol-Myers Squibb, GSK, Merck, Pfizer, Sandoz, Teva, Abbott, Aspen Pharmacare, AstraZeneca, Aurobindo Pharma, Basilea Pharmaceuticals, Baxter, Biocon, Corden Pharma, Eli Lilly, F. Hoffmann-La Roche, Flynn Pharma, Hospira, Incepta Pharmaceuticals, Johnson & Johnson, Kyorin Pharmaceutical, Lupin Pharmaceuticals, Orchid Pharma, Par Pharmaceutical, Pernix Therapeutics, Sanofi, Shionogi, Sun Pharmaceutical, Takeda Pharma, Theravance Biopharma, Wockhardt.